or
forgot password

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma


Phase 2
18 Years
61 Years
Not Enrolling
Both
Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin

Thank you

Trial Information

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma


To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic
peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by
following clinical outcomes and quality of life measures; and evaluate graft versus host
disease incidence and severity with regimen.


Inclusion Criteria:

Morphologically confirmed relapsed non-Hodgkin's lymphoma

Age: >18 and <61 years of age

Signed informed consent

Exclusion Criteria:Hepatic dysfunction defined by serum transaminases >2.5X normal values

Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min

Diseases other than non-Hodgkin's lymphoma

Prior bone marrow transplant procedure

Severe psychological or medical illness

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety

Outcome Time Frame:

unknown

Safety Issue:

Yes

Principal Investigator

Wen-Kai Weng

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

USA:IRB

Study ID:

BMT4L

NCT ID:

NCT00186394

Start Date:

April 2000

Completion Date:

December 2006

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • Blood and Marrow Transplant (BMT)
  • Lymphomas: Non-Hodgkin
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317